33 results about "Stem-cell therapy" patented technology

The invention discloses a surface-enhanced Raman probe as well as a preparation method and application thereof, and belongs to the technical field of biomedical imaging and stem cell therapy. The preparation method comprises the following steps: coating an ultrathin silver shell layer on the surface of gold nanoparticles to obtain Au-coated Ag particles; 4-sulfydryl phenylboronic acid pinacol ester molecules are modified on the surface of Au (at) Ag to form a Raman report layer, then sulfydryl-polyethylene glycol is introduced to realize biological orthogonal coupling, and the modified SERS probe is obtained through bovine serum albumin modification; jointly incubating the modified SERS probe and the azidation-labeled mouse bone marrow mesenchymal stem cells, so as to form an mmol / LSC-SERS composite probe; the obtained probe has good biocompatibility, stability and anti-interference capability and is suitable for a complex physiological environment, and the preparation method is simple and good in repeatability, is completely carried out in a water phase and does not need an organic solvent.

The present invention relates to the use of corneal cell-derived mitochondria for the prevention or treatment of corneal damage or corneal endothelial cell diseases. It has been confirmed that mitochondria isolated from corneal endothelial cells differentiated from induced pluripotent stem cells (iPSCs) of the present invention alleviate the inflammatory response of corneal endothelial cells in an inflammatory environment, restore the integrity and function of corneal endothelial cells, and, when delivered into heterologous primary corneal endothelial cells, suppress inflammatory responses, particularly inflammation caused by physical damage, and promote the regeneration of corneal endothelial cells. Therefore, mitochondria possessing such effects can overcome the tumorigenic limitations of conventional stem cell therapies, and due to their ease of production and minimal regulatory requirements, they offer excellent cost-effectiveness and broad applicability.

A silicon-anchored hardware enforcement system enables low-latency, cryptographically gated execution of artificial intelligence for stem cell therapy and regenerative medicine. A Sovereign Identity Token derived from a Physical Unclonable Function (PUF) permanently binds model decryption to a specific hardware instance and restricts execution to a Trusted Execution Environment synchronized to a hardware-protected Safety Epoch. Encrypted AI model weights are decryptable only upon successful hardware validation. Multimodal clinical inputs, including genetic, imaging, and structured patient data, are integrated through a hardware-constrained fusion architecture that operates under enforced biological safety parameters. FPGA-implemented predicate logic evaluates defined biological safety conditions at sub-millisecond latency, and an ASIC-based nullification circuit irreversibly suppresses outputs that violate hardware-defined thresholds within a bounded millisecond response time. A distributed revocation protocol propagates credential invalidation across networked nodes within sub-second latency while preserving reduced-capacity safe mode operation. A permissioned provenance ledger records hardware-attested execution events and supports automated regulatory documentation. The system provides secure clinical deployment, federated research enablement, and verifiable auditability for high-risk therapeutic environments.

The utility model discloses a cell culture detection box for stem cell treatment, and relates to the technical field of cell culture. The detection device comprises a detection box body, a mounting plate is arranged in the detection box body, a plurality of fixing grooves are formed in the mounting plate, a two-way screw rod is rotationally matched in the fixing grooves, a connecting rod is arranged at one end of the two-way screw rod, a handle is arranged at one end of the connecting rod, two moving blocks are in threaded fit with the two-way screw rod, and connecting plates are arranged on the moving blocks. And an elastic piece is arranged on one side of the connecting plate. According to the culture dish fixing device, the arc-shaped fixing plates located on the two moving blocks can be driven to move oppositely under the rotation of the two-way lead screw, so that the culture dishes can be fixed, and when the culture dishes with different sizes are fixed under the arrangement of the elastic pieces, the culture dishes can be fixed more conveniently. The culture dish is further fixed through the pressure of the elastic piece, so that the culture dish can be fixed more stably.

The present invention relates to adipose-derived stem cells (ASCs) and compositions, as well as methods for preparing and using such ASCs and compositions for therapy.

The invention discloses a bispecific antibody-UC-MSCs preparation for targeting prostate diseases as well as preparation and application of the bispecific antibody-UC-MSCs preparation. The preparation comprises a bispecific antibody BsAb-1 and human umbilical cord mesenchymal stem cells (UC-MSCs), the BsAb-1 is formed by connecting an anti-CD105 single-domain antibody, an anti-PSCA single-domain antibody and a flexible peptide linker in series, wherein the amino acid sequence of the BsAb-1 is as shown in SEQ ID NO: 4. According to the preparation, the UC-MSCs are delivered to a prostate focus through the targeting bridge effect of BsAb-1, the focus enrichment amount within 72 hours is increased by 6.3 times compared with that of pure UC-MSCs, and meanwhile retention of non-target organs such as the liver and the spleen is reduced. The preparation can effectively relieve inflammatory response and fibrosis of chronic prostatitis, and the curative effect of the preparation is remarkably superior to that of pure UC-MSCs treatment. Precise targeted treatment of prostate diseases is achieved, the curative effect is remarkably better than that of a traditional stem cell therapy method, and high clinical application value is achieved.

The present disclosure describes electrically stimulating biological systems using meshes, wherein the mesh comprises nanoscale wires and / or nanoelectronics. These may be embedded as a scaffold in biological structures, such as tissues, organoids, organs, organisms, and the like. These may be connectable to an external device to determine a property of the scaffold and / or to apply a stimulus to the biological structure. Certain embodiments are Al-driven systems designed for applications such as drug screening, stem cell therapy, or the like. In addition, some embodiments are directed to predictive models that can be used to predict and / or control the biological structure. For example, certain cells may be caused to mature more quickly, and / or the functionality of the biological structure may be enhanced or inhibited by using such models to apply suitable electrical stimuli to the biological structure, and / or portions of the biological structure.

The invention relates to a biological value method for evaluating the inflammation inhibition function of mesenchymal stem cells, and belongs to the technical field of stem cell treatment and biological evaluation of inflammatory diseases. The method provided by the invention has high sensitivity, high specificity and good repeatability, and is suitable for the titer evaluation of MSCs in the treatment of various inflammatory diseases. By introducing an IFNGR1 molecular index and a quantitative threshold judgment standard, a standardized and high-efficiency evaluation system from an evaluation mode depending on a'complex function experiment 'to a'molecular detection' is realized, and an innovative solution is creatively provided for standardized evaluation of the MSCs inflammation inhibition titer.

The invention discloses a cardiac function preparation as well as a preparation method and application thereof, and belongs to the technical field of preparation of cardiac muscle repair stem cell preparations. Performing mixed culture on endothelial progenitor cells and a heart extracellular matrix to obtain composite cell spheres; carrying out mixed culture on the myocardial-like cell sheet and the composite cell spheres, and after the composite cell spheres are uniformly distributed on the cell sheet and are in a fusion trend, cutting the composite cell spheres into pieces to obtain cell sheet-cell sphere composite particles; and uniformly mixing the composite particles with a poloxamer P407 solution to obtain the heart function preparation. Wherein the endothelial progenitor cells are combined with the cardiac extracellular matrix for use, so that angiogenesis in cardiac tissues can be effectively promoted, cell spheres and myocardial-like cell patches are compounded and cut into pieces, and the pieces can be better adhered to myocardial infarction positions for targeted repair. Experiments prove that the cardiac function preparation can effectively promote angiogenesis of cardiac tissue and myocardial infarction tissue repair, and the problem that the repair function is limited due to the fact that the number of survival cells is insufficient after cell transplantation in a stem cell therapy is solved.

This invention belongs to the field of cell culture technology, specifically relating to a method for preparing 3D hybrid cell microspheres and their applications. The invention involves co-seeding olfactory mucosal basal stem cells and olfactory mucosal mesenchymal stem cells in a low-absorption culture plate to obtain 3D hybrid cell microspheres. In the 3D hybrid culture system, the two cell types provide support for the state of the olfactory mucosal basal stem cells and olfactory mucosal mesenchymal stem cells, mutually supporting each other and further enhancing their biological characteristics, making them easier to colonize at lesion sites, thereby improving the anti-apoptotic ability of the 3D hybrid cell microspheres. The 3D hybrid cell microspheres prepared by this method offer promising applications for stem cell therapy of respiratory diseases and provide a foundation for using olfactory mucosal-derived stem cells in regenerative medicine.

The present application relates to a kind of mesenchymal stem cells of overexpressing HDAC9 and its preparation method and application, belong to stem cell therapy technical field.The present application overexpressing HDAC9 mesenchymal stem cell includes the nucleotide sequence as shown in SEQ ID NO:1 or SEQ ID NO:2 and dCas9-target plasmid.The present application constructs MSCs of HDAC9 gene modification for the first time, improves its inhibition effect to immune inflammation, so as to promote its treatment effect in immune inflammation.

This invention discloses a neutral homogeneous polysaccharide from Rehmannia glutinosa, its preparation method, and its applications, belonging to the field of traditional Chinese medicine preparation technology. The polysaccharide is mainly composed of galactose, glucose, and fructose in a molar ratio of 2.72:1.17:1.11, with a weight-average molecular weight of 2152 Da. The neutral polysaccharide from Rehmannia glutinosa can exert a therapeutic effect on osteoporosis by increasing bone mineralization and bone density; it can also promote the proliferation and osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs), showing significant application effects in the preparation of stem cell therapy drugs for bone defects. The neutral homogeneous polysaccharide from Rehmannia glutinosa shows great application potential in the preparation of drugs for treating osteoporosis and as a stem cell therapy (especially bone regeneration therapy based on bone marrow mesenchymal stem cells). This provides new candidate substances and research directions for developing efficient and safe treatment strategies for bone metabolic diseases derived from traditional Chinese medicine.

Exemplary light control devices and methods provide a regional variation of visual information and sampling (“V-VIS”) of an ocular field of view that improves or stabilizes vision, ameliorates a visual symptom, reduces the rate of vision loss, or reduces the progression of an ophthalmic or neurologic condition, disease, injury or disorder. The V-VIS devices and methods generate a moving aperture effect anterior to a retina that samples and delivers to the retina environmental light from an ocular field of view at a sampling rate between 50 hertz and 50 kilohertz. Certain of these V-VIS devices and methods may be combined with augmented or virtual reality, vision measurement, vision monitoring, or other therapies including, but not limited to, pharmacological, gene, retinal replacement and stem cell therapies.

An in vitro method of preparing a population of hypoimmune mammalian stem cells includes providing a population of isolated mammalian stem cells, wherein the isolated mammalian stem cells express a cell adhesion molecule; and modifying the expression of the cell adhesion molecule in the population of isolated mammalian stem cells to decrease or knockout expression of the cell adhesion molecule and provide the population of hypoimmune mammalian cells. The population of isolated mammalian stem cells can be pluripotent stem cells, or embryonic stem cells, and can be human or non-human stem cells.

The invention relates to bioinformatics technology and specifically to an analysis method of a spatial transcriptome-based 4D-printed stem cell scaffold for enhancing diabetic skin injury healing. Spatial transcriptome sequencing is performed on tissues from both the PBS group and the combined treatment group. Cell clustering and annotation identify main cell types, followed by visualization of their spatial distributions in both groups. The proportions of various cell types are statistically quantified and plotted. Cell subsets exhibiting significant differential gene expression are enriched and verified. Using a 4D-printed stem cell scaffold combined with a piRNA inhibitor and stem cell therapy, the method reveals spatial distribution and dynamic cellular changes during wound healing. It identifies precise cellular locations and gene expression patterns within tissues, providing critical insights into the biological processes by which biomaterials promote diabetic injury repair. This approach offers new directions for future drug development.

This invention discloses a stem cell preparation for septic cardiomyopathy that targets and regulates LCN2, and its preparation method, belonging to the field of biomedical technology. Addressing the technical problems of insufficient targeting, weak LCN2 regulation, and limited efficacy in treating septic cardiomyopathy associated with traditional umbilical cord mesenchymal stem cell preparations in the prior art, this invention provides a stem cell preparation for septic cardiomyopathy that targets and regulates LCN2, and its preparation method. Using umbilical cord mesenchymal stem cells as a carrier, it achieves precise intervention on LCN2, enhances the repair capacity of umbilical cord mesenchymal stem cells for septic myocardial damage, and provides a new stem cell therapy option for septic cardiomyopathy that is highly targeted, has definite efficacy, and is highly safe.

The application relates to the technical field of stem cell engineering and regenerative medicine, and specifically discloses a stem cell treatment method for treating type 2 diabetes. The method comprises the following steps: S1, extracting placenta-derived mesenchymal stem cells; S2, performing multi-gene modification on the mesenchymal stem cells to obtain gene-modified mesenchymal stem cells; S3, pretreating the gene-modified mesenchymal stem cells with a culture medium; S4, extracting microvesicles from the mesenchymal stem cells; S5, mixing the microvesicles, baicalin, L-arginine and vitamin D in a buffer to form a composite preparation; S6, introducing the composite preparation into a patient's body through abdominal cavity intervention; and S7, performing synergistic treatment by combining oral administration of an SGLT2 inhibitor after infusion, and regularly monitoring islet function indexes. The stem cell treatment method can be used for treating type 2 diabetes, and has the advantages of being targeted to improve the islet microenvironment, promoting the recovery of beta cell function and being durable in action.

The invention relates to a Raman spectrum biochemical component decomposition and mixing method based on a depth automatic encoder and self-adaptive spectrum shift, which comprises the following steps: acquiring Raman spectrum of a single cell, and constructing a data set; the data set is preprocessed; constructing a deep automatic encoder neural network model, and training the deep automatic encoder neural network model by using the preprocessed data set; wherein the deep automatic encoder neural network model comprises a feature extraction encoder and a spectrum reconstruction decoder; and performing biochemical component decomposition and mixing of the Raman spectrum by using the trained deep automatic encoder neural network model. According to the invention, component characteristics can be automatically extracted from a complex Raman spectrum, high-precision, dynamic and interpretable unmixing analysis is realized, and an innovative tool is provided for automatic production and real-time quality control of stem cell treatment products.

Exemplary light control devices and methods provide a regional variation of visual information and sampling (“V-VIS”) of an ocular field of view that improves or stabilizes vision, ameliorates a visual symptom, reduces the rate of vision loss, or reduces the progression of an ophthalmic or neurologic condition, disease, injury or disorder. The V-VIS devices and methods generate a moving aperture effect anterior to a retina that samples and delivers to the retina environmental light from an ocular field of view at a sampling rate between 50 hertz and 50 kilohertz. Certain of these V-VIS devices and methods may be combined with augmented or virtual reality, vision measurement, vision monitoring, or other therapies including, but not limited to, pharmacological, gene, retinal replacement and stem cell therapies.

The present application relates to a kind of degradable cationic polymer with bone targeting function and its preparation method and application, specifically, the degradable cationic polymer with bone targeting function provided in the present application can effectively load nucleic acid (such as mRNA, miRNA, DNA), and the encapsulation efficiency is more than 90%, and stable nanoparticles are formed by electrostatic interaction, protect nucleic acid from degradation, while having the characteristics of slowing down particle positive electricity.This carrier shows better stability compared with LNP, supports long-term storage at low temperature.Its bone targeting is clear, promotes the accurate delivery of nucleic acid to bone tissue, enhances the efficacy and reduces side effects, while showing biocompatibility for osteoblasts without toxicity.The application range is wide, covering osteoporosis, osteoarthritis, bone tumor treatment and gene and stem cell therapy.Experiments have verified that the nanoparticles formed by the carrier and eGFP mRNA have high transfection efficiency, and the combination with miRNA effectively inhibits breast cancer bone metastasis, highlighting its therapeutic potential.

The invention relates to a method for constructing a functional micro-nano material engineered stem cell based on a biological orthogonal reaction, and belongs to the technical field of biomedicine.The method comprises the steps that a functional micro-nano material with a biological orthogonal reaction group reacts with stem cells marked by the corresponding biological orthogonal reaction group, engineering transformation of the stem cells is achieved, and the stem cells are obtained. Therefore, the functional micro-nano material engineered stem cells are constructed. The functional micro-nano material can be used as a drug carrier to load and slowly release various drugs, or accurately regulate and control the stem cells by depending on the physicochemical properties of the functional micro-nano material, so that the functions of the stem cells are enhanced, and the application effect of the functional micro-nano material in tissue repair and disease treatment is improved. According to the method, genetic engineering operation is not needed, complex steps for gene modification of the stem cells are avoided, operation is easy and convenient, reaction conditions are mild, good biocompatibility and controllability are achieved, a safe, efficient and generalizable new strategy is provided for functional micro-nano material engineered stem cells, the treatment effect of the stem cells is improved, and the method has good application prospects. Wide application prospects are realized.

This invention discloses a small molecule composition for restoring the immunomodulatory function of senescent mesenchymal stem cells (MSCs) and its applications. It belongs to the field of biomedical technology. The small molecule composition comprises resveratrol, quercetin, ginsenoside Rg1, and N-(4-phenylbutyl)acetamide in a weight ratio of 1:2:2:1. Experiments show that this composition significantly reduces the SA-β-gal positivity rate of senescent MSCs (from 76.3% to 11.2%), inhibits T cell proliferation by 89.7%, and reduces TNF-α and IFN-γ by 76.8% and 77.5%, respectively, with significantly better effects than the individual use of each component or any combination of the three drugs. Pathway inhibitor recovery experiments confirm that its synergistic effect depends on the simultaneous activation of multiple pathways. This composition can be used to prepare drugs or cell culture additives for restoring the immunomodulatory function of senescent MSCs, providing a new approach for stem cell therapy of age-related diseases.

The function of enhancing stem cells is accomplished with a specific transfected human gene type into a stem cell of choice to allow for the regenerative potential of the selected stem cell to be greatly enhanced by combining both gene and stem cell therapies together. Specific genes for selected protein production are cultured with a stem cell of choice which then produces a supernatant composed of an exosome-gene complex. This exosome-gene complex can also be used as a therapeutic gene therapy on its own or in combination with a stem cell gene complex together for a specific cellular effect, organ or tissue of regenerative effect or general systemic result.

The present invention relates to a composition for bone regeneration comprising METTL7A-overexpressing stem cells, a method for preparing the same, and a cell therapy product comprising the same. According to the invention, it is possible to enhance the osteogenic differentiation ability and viability of stem cells compared to conventional stem cell therapy products for bone regeneration.

This utility model relates to a cell culture testing box for stem cell therapy, and more particularly to a cell culture testing box for stem cell therapy, comprising a box body, a microscope, a second sealing door, and a culture medium. The microscope is fixed to the top of the box body, the second sealing door is rotatably connected to the side wall of the box body, a glove is fixed to the side wall of the box body, and a transfer box is embedded in the side wall of the box body near the glove. The end of the transfer box is rotatably connected to a first sealing door. Compared with traditional cell culture testing boxes for stem cell therapy, this utility model, through the cooperation of the transfer box, the first sealing door, the sliding cover, and the nozzle, can reduce the entry of external air and bacteria into the box body. The cooperation of the sliding cover and the sliding groove improves the stability of the sliding cover movement. The cooperation of the glove and the lever improves the convenience of opening the sliding cover, making it convenient for operators to pour the nutrient solution inside the transfer box into the culture medium, thereby improving the safety of the stem cell culture process and thus increasing the survival rate.

The present invention relates to the treatment of inherited retinal diseases using stem cell therapy. In particular, the present disclosure relates to methods of using photoreceptor precursor cells to treat primary photoreceptor diseases via surgical administration to the eye of a subject.

Human skeletal muscle stem cells were generated from facioscapulohumeral muscular dystrophy (FSHD) and healthy control iPSC using a transgene-free skeletal muscle differentiation protocol and production of stable iMyoblasts. Analyses revealed that FSHD and healthy control iMyoblasts are embryonic-like myogenic cells that undergo myotube differentiation ex vivo by growth factor depletion and are efficiently transplantable into the tibialis anterior (TA) muscles of NSG mice, where human muscle under-goes embryonic-to-adult myosin isoform switching. The DUX4 FSHD disease gene maintains its hypomethylated disease state inFSHD iPSC and iMyoblast, and its expression is upregulated during myotube differentiation and in muscle xenografts. Consequently, these iMyoblasts accurately exhibit the molecular pathology of human muscular dystrophies and are useful for the development of drug, gene editing and stem cell therapeutics.

The application belongs to the technical field of genetic engineering and cell modification, and discloses a genetic engineering construction method and application of an anti-apoptosis human mesenchymal stem cell. The application realizes a breakthrough improvement through specific lactic acidification mutation at the HDAC1 K412 site, for example, precise gene editing mediated by CRISPR-Cas9, only a single amino acid site is changed, that is, K412R mutation simulates continuous lactic acidification, and the whole genome epigenetic modification disturbance can be avoided; and the modification is not dependent on exogenous metabolic substrate, and the negative feedback effect of traditional metabolic intervention is overcome; the mutant continuously inhibits the P53 apoptosis pathway, and the ability of MSC to resist oxidative stress-mediated apoptosis is significantly improved. The design concept of "one target point and one regulation" fundamentally solves the core contradiction that the prior art cannot consider long-acting and specificity at the same time, and provides a new paradigm for stem cell therapy.

The function of enhancing stem cells with a specific transfected human gene type into a stem cell of choice to allow for the regenerative potential of the selected stem cell to be greatly enhanced by combining both gene and stem cell therapies together. Specific genes for selected protein production are cultured with a stem cell of choice which then produces a supernatant composed of an exosome-gene complex. This exosome-gene complex can also be used as a therapeutic gene therapy on its own or in combination with a stem cell gene complex together for a specific cellular effect, organ or tissue of regenerative effect or general systemic result.